Health Care & Life Sciences » Pharmaceuticals | GreenPeptide Co. Ltd.

GreenPeptide Co. Ltd. | Cash Flow

Fiscal year is April-March. All values JPY Thousands.
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
19,412.00
408,432.00
992,977.00
1,116,928.00
1,573,292.00
1,880,529
Depreciation, Depletion & Amortization
3,629.00
8,802.00
19,304.00
42,707.00
73,210.00
82,770
Other Funds
60,566.00
15,893.00
1,841.00
18,107.00
30,929.00
239,284
Funds from Operations
37,525.00
415,523.00
975,514.00
1,056,113.00
1,469,154.00
1,558,472
Changes in Working Capital
75,012.00
31,675.00
66,802.00
11,399.00
122,182.00
100,901
Net Operating Cash Flow
37,487.00
447,198.00
908,712.00
1,067,512.00
1,591,336.00
1,457,571
Capital Expenditures
3,688.00
42,863.00
32,125.00
103,842.00
111,555.00
Sale of Fixed Assets & Businesses
-
-
-
7,277.00
-
Purchase/Sale of Investments
-
21,348.00
-
-
-
Net Investing Cash Flow
3,688.00
66,854.00
32,125.00
96,564.00
111,556.00
Net Financing Cash Flow
-
1,247,716.00
2,672,558.00
3,559,188.00
3,281,082.00
Net Change in Cash
33,799.00
733,664.00
1,731,721.00
2,395,112.00
1,578,190.00
Free Cash Flow
33,799.00
487,750.00
931,235.00
1,164,749.00
1,699,554.00
Change in Capital Stock
-
1,247,716.00
2,672,558.00
3,559,187.00
3,281,082.00
Other Uses
-
2,643.00
-
-
-

About GreenPeptide Co.

View Profile
Address
Fukuoka Bio Incubation Center 402
Kurume Fukuoka 839
Japan
Employees -
Website http://www.brightpathbio.com
Updated 07/08/2019
BrightPath Biotherapeutics Co., Ltd. engages in the drug development business. It focuses on the development of cancer immunotherapies. Its product candidates are based on peptide vaccine technology that stimulates a potent immune response to tumor-associated antigens.